BioCentury
ARTICLE | Clinical News

Summit craters after ending DMD program

June 27, 2018 6:57 PM UTC

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy. Summit sank 160p (81%) to 37.50p in London, and was off $10.10 (80%) to $2.55 on NASDAQ.

PhaseOut DMD enrolled 40 DMD patients ages 5-10. Ezutromid missed the open-label study's primary endpoint of change in MRI leg muscle parameters after 48 weeks of treatment, as well as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin UTRN modulator...